BioCentury | Nov 18, 1996
Emerging Company Profile

Advanced Therapies: 'Artificial' vectors

...served as CEO of Biovector Therapeutics S.A. (Toulouse, France). Ullman also held management positions at Liposome Technology Inc....
BioCentury | Jul 3, 1995
Company News

Sequus drug delivery news

...SEQU (formerly Liposome Technology Inc. ) named board member I. Craig Henderson as CEO and hired L. Scott...
BioCentury | Jul 3, 1995
Clinical News

Liposomal doxorubicin coated with polyethylene glycol data

...SEQU (formerly Liposome Technology Inc. , Menlo Park, Calif.) said that two dose-ranging, Phase I trials of the...
...was hair loss. Four Phase II trials are underway. SEQUUS Pharmaceuticals Inc. (SEQU) SEQU (formerly Liposome Technology Inc....
BioCentury | Jun 12, 1995
Analyst Picks & Changes

Analyst picks & changes

Liposome Technology Inc. (LTIZ) NeXstar Pharmaceuticals Inc. (NXTR) Oppenheimer's Geller, in a comparison of NXCO's DaunoXome liposomal daunorubicin and LTIZ's Doxil Stealth liposome formulation of doxorubicin, concluded that daunorubicin is less potent and less widely...
BioCentury | Jun 5, 1995
Analyst Picks & Changes

Analyst picks & changes

...The Liposome Co. Inc. (LIPO) Liposome Technology Inc. (LTIZ) NeXstar Inc. (NXTR) Based on a comparison of the...
BioCentury | May 30, 1995
Analyst Picks & Changes

Analyst picks & changes

Liposome Technology Inc. (LTIZ) Oppenheimer's Geller said he believes that speculation about a potential buyout of LTIZ is incorrect. He said the company probably will announce a marketing partnership for Doxil in a few weeks,...
BioCentury | May 22, 1995
Clinical News

Doxil polyethylene glycol-conjugated liposomes containing doxorubicin data

...submitted to the FDA, and all further details will be released at a medical meeting. Liposome Technology Inc....
BioCentury | Apr 24, 1995
Analyst Picks & Changes

Analyst picks & changes

Liposome Technology Inc. (LTIZ) Robertson, Stephens analyst Edward Hurwitz said recent management changes at LTIZ set the stage for a company turnaround. The resignations — of Chairman and CEO Nick Arvanitidis, Senior Medical Officer Richard...
BioCentury | Apr 24, 1995
Strategy

Liposome Tech looks for a new crew

Liposome Technology Inc. completed the first phase of a management restructuring, with the announcement that CFO Peter Leigh will leave the Menlo Park, Calif., company. Chairman and CEO Nick Arvanitidis already has said he will...
BioCentury | Feb 27, 1995
Clinical News

Liposome Tech regulatory update

Liposome Technology Inc. (LTIZ) LTIZ (Menlo Park, Calif.) filed for Israeli approval of Amphocil , its lipid-complexed formulation of amphotericin B. The company is seeking approval to treat severe systemic and/or deep mycoses in cases where...
Items per page:
1 - 10 of 43
BioCentury | Nov 18, 1996
Emerging Company Profile

Advanced Therapies: 'Artificial' vectors

...served as CEO of Biovector Therapeutics S.A. (Toulouse, France). Ullman also held management positions at Liposome Technology Inc....
BioCentury | Jul 3, 1995
Company News

Sequus drug delivery news

...SEQU (formerly Liposome Technology Inc. ) named board member I. Craig Henderson as CEO and hired L. Scott...
BioCentury | Jul 3, 1995
Clinical News

Liposomal doxorubicin coated with polyethylene glycol data

...SEQU (formerly Liposome Technology Inc. , Menlo Park, Calif.) said that two dose-ranging, Phase I trials of the...
...was hair loss. Four Phase II trials are underway. SEQUUS Pharmaceuticals Inc. (SEQU) SEQU (formerly Liposome Technology Inc....
BioCentury | Jun 12, 1995
Analyst Picks & Changes

Analyst picks & changes

Liposome Technology Inc. (LTIZ) NeXstar Pharmaceuticals Inc. (NXTR) Oppenheimer's Geller, in a comparison of NXCO's DaunoXome liposomal daunorubicin and LTIZ's Doxil Stealth liposome formulation of doxorubicin, concluded that daunorubicin is less potent and less widely...
BioCentury | Jun 5, 1995
Analyst Picks & Changes

Analyst picks & changes

...The Liposome Co. Inc. (LIPO) Liposome Technology Inc. (LTIZ) NeXstar Inc. (NXTR) Based on a comparison of the...
BioCentury | May 30, 1995
Analyst Picks & Changes

Analyst picks & changes

Liposome Technology Inc. (LTIZ) Oppenheimer's Geller said he believes that speculation about a potential buyout of LTIZ is incorrect. He said the company probably will announce a marketing partnership for Doxil in a few weeks,...
BioCentury | May 22, 1995
Clinical News

Doxil polyethylene glycol-conjugated liposomes containing doxorubicin data

...submitted to the FDA, and all further details will be released at a medical meeting. Liposome Technology Inc....
BioCentury | Apr 24, 1995
Analyst Picks & Changes

Analyst picks & changes

Liposome Technology Inc. (LTIZ) Robertson, Stephens analyst Edward Hurwitz said recent management changes at LTIZ set the stage for a company turnaround. The resignations — of Chairman and CEO Nick Arvanitidis, Senior Medical Officer Richard...
BioCentury | Apr 24, 1995
Strategy

Liposome Tech looks for a new crew

Liposome Technology Inc. completed the first phase of a management restructuring, with the announcement that CFO Peter Leigh will leave the Menlo Park, Calif., company. Chairman and CEO Nick Arvanitidis already has said he will...
BioCentury | Feb 27, 1995
Clinical News

Liposome Tech regulatory update

Liposome Technology Inc. (LTIZ) LTIZ (Menlo Park, Calif.) filed for Israeli approval of Amphocil , its lipid-complexed formulation of amphotericin B. The company is seeking approval to treat severe systemic and/or deep mycoses in cases where...
Items per page:
1 - 10 of 43